May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Effect of Flunarizine, a Calcium Channel Blocker, on Intraocular Pressure (IOP) in Glaucomatous Monkey Eyes
Author Affiliations & Notes
  • R.–F. Wang
    Ophthalmology, Mt Sinai School of Medicine, New York, NY
  • D.J. Gagliuso
    Ophthalmology, Mt Sinai School of Medicine, New York, NY
  • T.W. Mittag
    Ophthalmology, Mt Sinai School of Medicine, New York, NY
  • S.M. Podos
    Ophthalmology, Mt Sinai School of Medicine, New York, NY
  • Footnotes
    Commercial Relationships  R. Wang, None; D.J. Gagliuso, None; T.W. Mittag, None; S.M. Podos, Alcon Laboratories, Inc. C; Pfizer, Inc. C.
  • Footnotes
    Support  NIH grant EY01867 and an unrestricted grant from RPB
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3778. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.–F. Wang, D.J. Gagliuso, T.W. Mittag, S.M. Podos; Effect of Flunarizine, a Calcium Channel Blocker, on Intraocular Pressure (IOP) in Glaucomatous Monkey Eyes . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3778.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Topical administration of flunarizine, a non selective calcium channel blocker, reduces IOP in rabbits and in normal monkeys. This study evaluates the effect of flunarizine on IOP in single–dose or multiple–dose applications in monkey eyes with unilateral laser–induced glaucoma. Methods: 8 glaucomatous monkeys were used in this study. IOP was measured hourly for 6 hrs on each day of the study. Following one day of baseline IOP measurement, 50µl drop (25µl x 2) was topically applied to the glaucomatous eye with 0.5%, 1% or 2% concentrations. A multiple–dose study was performed with 0.5% flunarizine twice daily for 5 consecutive days. IOP was measured for one baseline day, one vehicle– treated day and treatment days 1,3 and 5. Results: Unilateral topical application of 50µl of 0.5%, 1% or 2% flunarizine to the glaucomatous eye of 8 monkeys reduced IOP (p<0.05) bilaterally. A significant (p<0.01) reduction in IOP occurred for 2 hrs, 3 hrs and 5 hrs, and was up to 2.5 ± 0.5 (mean ± SEM) mmHg (9%), 3.0 ± 0.4 mmHg (10%), and 5.0 ± 0.8 mmHg (18%) in the glaucomatous eyes following doses of the 0.5%, 1% and 2% concentrations, respectively. In the fellow untreated control eyes, a significant (p<0.05) reduction in IOP was observed for 1–2 hrs with the maximum reduction in IOP of 1.3 ± 0.5 mmHg (7%), 1.5 ± 0.3 mmHg (8%) and 2.9 ± 0.7 mmHg (15%) following unilateral application of 0.5%, 1% or 2% flunarizine. The ocular hypotensive effect was enhanced with twice daily administration of 0.5% flunarizine for 5 days. The IOP was significantly (p<0.01) reduced for 2 hrs after the first dose and for at least 6 hrs after the fifth dose. The maximum reduction in IOP was 2.5 ± 0.5 mmHg (9%) on day 1 and 6.0 ± 0.8 mmHg (21%) on day 5 in the treated glaucomatous monkey eyes, and 1.3 ± 0.5 mmHg (7%) on day 1 and 1.5 ± 0.6 mmHg (8%) on day 5 in the untreated contralateral normal eyes. Mild conjunctival discharge appeared in some eyes treated with 0.5% flunarizine. More conjuctival discharge, mild conjuctival hyperemia, eyelid edema and cornea edema appeared in some eyes treated with the 1% and 2% concentrations. Conclusions: Flunarizine reduces IOP in a dose–dependent manner when administered to glaucomatous monkey eyes, but also has some effect on the contralateral, untreated eyes.

Keywords: intraocular pressure • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×